Results 151 to 160 of about 101,610 (217)

Granulocyte colony-stimulating factor plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia: a multicenter phase 2 trial. [PDF]

Blood Cancer J
Wang H, Wang X, Shi T, Wei S, Li X, Leng Y, Wu Y, Sun M, He P, Zhu HH.   +9 more
europepmc   +1 more source

Progressive Pulmonary Alveolar Proteinosis Diagnosis Masking Pneumonic Lung Carcinoma: Anchoring Bias in Critical Care

Cytopathology, EarlyView.
A presumed case of pulmonary alveolar proteinosis with clinical deterioration was ultimately identified at autopsy as pneumonic‐type pleomorphic carcinoma. This case highlights the diagnostic overlap between diffuse lung diseases and the risk of anchoring bias in critically ill patients.
Dakota Wheeler, Rhaya Murray, Teklu Legesse, Hector Mesa   +3 more
wiley   +1 more source

Granulocyte colony-stimulating factor-producing cutaneous squamous cell carcinoma: A case report and literature review. [PDF]

Medicine (Baltimore)
Ishiguro A, Iwashita N, Otani M, Watanabe D.   +3 more
europepmc   +1 more source

The different face of skin‐rash induced by brentuximab vedotin

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background: Brentuximab vedotin (BV) is a targeted therapy for CD30‐expressing lymphomas, including Hodgkin lymphoma (HL) and cutaneous T‐cell lymphoma (CTCL). While peripheral neuropathy is the most common adverse event, BV‐induced skin rashes are less frequent and not well characterized.
Alessandro Pileri, Tullio Brunetti, Serena Rupoli, Gianluca Cafasso, Corrado Zengarini, Staphano Cedirian, Federico Bardazzi, Cosimo Misciali, Michela Starace, Claudio Agostinelli, Gaia Goteri, Erika Morsia   +11 more
wiley   +1 more source

Acute Lung Injury in a Healthy Peripheral Blood Stem Cell Donor Following Granulocyte-colony Stimulating Factor Administration: A Case Report. [PDF]

EJHaem
Desai N, Moya TA, Heffering-Cardwell M, Sanchez FT, Michelis FV, Law AD.   +5 more
europepmc   +1 more source

Dose‐Adjusted Treatment With 7‐Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia

European Journal of Haematology, EarlyView.
ABSTRACT Acute myeloid leukaemia (AML) in older or unfit patients is commonly treated with hypomethylating agents (HMA) plus venetoclax (VEN), but prolonged VEN exposure often causes substantial haematological toxicity. We retrospectively analysed 61 elderly AML patients treated with HMA + VEN for 7 (7d), 14 (14d) or > 14 days (> 14d) per cycle.
Laurenz Steiner, Lina S. Silva‐Bermudez, Mahmoud Ghazal, Mohammed Abba, Catharina Gerhards, Georgia Metzgeroth, Alice Fabarius, Stefan Klein, Sebastian Kreil, Nanni Schmitt, Patrick Wuchter, Wolf‐Karsten Hofmann, Alexander Streuer   +12 more
wiley   +1 more source

Efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor as a support for chemotherapy for gestational trophoblastic neoplasia: a propensity score matching analysis. [PDF]

Front Oncol
Zhao X, Zhao H, Sun L, Yan L, Han H, Li Z.   +5 more
europepmc   +1 more source

Prospective Study of Targeted Busulfan–Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Genetic Rare Diseases

European Journal of Haematology, EarlyView.
ABSTRACT Objectives Genetic rare diseases (GRDs), including chronic granulomatous disease, familial hemophagocytic lymphohistiocytosis, and congenital neutropenia, often require hematopoietic stem cell transplantation (HSCT) as the only curative option.
Bo Kyung Kim, Kyung Taek Hong, Jung Yoon Choi, Hyun Jin Park, Kyung‐Sang Yu, In‐Jin Jang, Hyoung Jin Kang   +6 more
wiley   +1 more source

Pegylated recombinant human granulocyte colony-stimulating factor enhances radiotherapy completion and safety in concurrent chemoradiotherapy for cervical cancer: a retrospective analysis. [PDF]

Front Oncol
Zhao L, Zhai Y, Meng L, Ren Y, Liu N, Xing X, Wen X, Niu G.   +7 more
europepmc   +1 more source